Physician profile
Paul Dejac
NPI 1457796997
$3,772.25
in general payments reported to CMS, 2019-2025
25 companies · $1,240 in 2025
The $1,240 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $42.55 · 2021: $19.80 · 2022: $16.64 · 2023: $1,125 · 2024: $1,328 · 2025: $1,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,693.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $482.46 | 2023-2025 | Octrode, Axium, Proclaim |
| Novo Nordisk INC | $465.76 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $383.67 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $350.22 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $305.02 | 2023-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $278.66 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $196.48 | 2023-2025 | Rexulti |
| Baxter Healthcare | $161.89 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Gilead Sciences, INC. | $155.81 | 2023-2025 | |
| Astellas Pharma US INC | $149.98 | 2023-2025 | Veozah |
| Shield Therapeutics INC | $143.19 | 2023-2025 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.29 | 2024 | Relistor |
| Exact Sciences Corporation | $111.50 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $98.08 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Lundbeck LLC | $91.21 | 2024-2025 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.55 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $57.05 | 2020-2022 | |
| Cumberland Pharmaceuticals, INC. | $35.72 | 2024 | Kristalose |
| Hologic Sales and Service, LLC | $23.75 | 2024 | Aptima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.94 | 2020 | |
| Scilex Pharmaceuticals INC. | $21.44 | 2025 | |
| Phathom Pharmaceuticals, INC. | $18.16 | 2025 | Voquezna |
| Optinose US, INC. | $15.92 | 2024 | |
| Dexcom, INC. | $13.50 | 2023 | Dexcom G6 Transmitter |
| Vivaquant INC, Dba Rhythm Express | $13.00 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Dejac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.